Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
Status:
Completed
Trial end date:
2021-05-19
Target enrollment:
Participant gender:
Summary
There is a growing need to develop pharmacologic interventions to improve metabolic function
in women with polycystic ovary syndrome (PCOS). Given that PCOS is a frequent condition and
weight loss is essential but difficult to achieve, it is important to study if the effect on
body weight reported in other studies can be confirmed in a selected population of
hyperandrogenic patients, especially with medications currently approved for weight
reduction. High dose liraglutide alone results in significant weight reduction in obese women
without PCOS. There is limited data on weight loss with high dose liraglutide in non-diabetic
females with PCOS treated with this agent . Studies on the effect of anti-obesity medication
combined with lifestyle changes on body weight and composition and androgen excess in obese
women diagnosed with PCOS are lacking. The investigators aim to elucidate the most
efficacious weight reduction regime in obese PCOS women. The investigators further hope to
determine which treatment(s) addressing the multifaceted disturbances of this disorder in
patients with PCOS and obesity emerges as the preferable therapy.